Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Between December 30, 2024, and January 3, 2025, Essity Aktiebolag (publ) repurchased a total of 162,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved ...

The highly anticipated 2024-2025 Global Top Brands Award Ceremony and International Consumer Electronics Industry Leaders' Summit were held on January 8, 2025 local time, at the Wynn & Encore Hotel in ...

Leo Pharma, meanwhile, announced this fall that it had submitted its delgocitinib cream for FDA approval as a treatment for adults with moderate to severe CHE for whom topical corticosteroids ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Stocks like Tata Steel, Dr Reddy’s Laboratories, WPIL, Rail Vikas Nigam, Mahindra and Mahindra, Mankind Pharma, CESC, ...

Ingenol mebutate is under clinical development by Leo Pharma and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell ...

Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company ...